129 related articles for article (PubMed ID: 1208551)
1. Serum renin and renin substrate levels in scleroderma.
Fleischmajer R; Gould AB
Proc Soc Exp Biol Med; 1975 Nov; 150(2):374-9. PubMed ID: 1208551
[No Abstract] [Full Text] [Related]
2. Cutaneous fibrinolytic activity in scleroderma.
Lotti T; Cerinic MM; Marmugi D; Fabbri P
Clin Exp Rheumatol; 1985; 3(3):249-53. PubMed ID: 4053443
[TBL] [Abstract][Full Text] [Related]
3. The pathophysiology of the fibrosis in scleroderma skin.
Fleischmajer R; Perlish JS
Prog Clin Biol Res; 1984; 154():381-404. PubMed ID: 6382305
[No Abstract] [Full Text] [Related]
4. In vivo study of scleroderma by non-invasive techniques.
Kalis B; De Rigal J; Léonard F; le Lévêque JL; De Riche O; Corre YL; Lacharriere OD
Br J Dermatol; 1990 Jun; 122(6):785-91. PubMed ID: 2369559
[TBL] [Abstract][Full Text] [Related]
5. Influence of childhood scleroderma on physical function and quality of life.
Baildam EM; Ennis H; Foster HE; Shaw L; Chieng AS; Kelly J; Herrick AL; Richards HL
J Rheumatol; 2011 Jan; 38(1):167-73. PubMed ID: 21041272
[TBL] [Abstract][Full Text] [Related]
6. [Systemic sclerosis (scleroderma) without scleroderma].
Nadashkevych ON
Lik Sprava; 2001; (3):93-4. PubMed ID: 11560041
[TBL] [Abstract][Full Text] [Related]
7. [Microcirculation and the nature of morphological changes in the gastric and duodenal mucosa in children with scleroderma].
Vlasova TM; Sokolovskiĭ GA; Chumakov AM; Daurova NV; Uvarova NN
Pediatriia; 1983 Nov; (11):48-50. PubMed ID: 6669435
[No Abstract] [Full Text] [Related]
8. Serum tissue inhibitor of metalloproteinases in patients with systemic sclerosis.
Kikuchi K; Kubo M; Sato S; Fujimoto M; Tamaki K
J Am Acad Dermatol; 1995 Dec; 33(6):973-8. PubMed ID: 7490368
[TBL] [Abstract][Full Text] [Related]
9. [Morphological changes in the skin in scleroderma in the process of treatment with unithiol].
Dubinskiĭ AA; Tseraidis GS; Guĭda PP; Petrusenko EA; Babykina EA
Vrach Delo; 1978 Oct; (10):112-4. PubMed ID: 716343
[No Abstract] [Full Text] [Related]
10. Cellular infiltrates in scleroderma skin.
Fleischmajer R; Perlish JS; Reeves JR
Arthritis Rheum; 1977 May; 20(4):975-84. PubMed ID: 861067
[TBL] [Abstract][Full Text] [Related]
11. Successful treatment of scleroderma with PUVA therapy.
Kanekura T; Fukumaru S; Matsushita S; Terasaki K; Mizoguchi S; Kanzaki T
J Dermatol; 1996 Jul; 23(7):455-9. PubMed ID: 8772023
[TBL] [Abstract][Full Text] [Related]
12. [Connective tissue compartments in scleroderma. Study of the structure and the biomechanical properties].
Pierard GE; Pierard-Franchimont C; Lapière CM
Dermatologica; 1985; 170(3):105-13. PubMed ID: 3979637
[TBL] [Abstract][Full Text] [Related]
13. Effects of calcitriol on fibroblasts derived from skin of scleroderma patients.
Boelsma E; Pavel S; Ponec M
Dermatology; 1995; 191(3):226-33. PubMed ID: 8534941
[TBL] [Abstract][Full Text] [Related]
14. [Hemostasis in patients with circumscribed and systemic scleroderma].
Dovzhanskiĭ SI; Gerasimova MV
Vestn Dermatol Venerol; 1988; (1):41-3. PubMed ID: 3364021
[No Abstract] [Full Text] [Related]
15. Histopathologic differentiation between localized and systemic scleroderma.
Torres JE; Sánchez JL
Am J Dermatopathol; 1998 Jun; 20(3):242-5. PubMed ID: 9650695
[TBL] [Abstract][Full Text] [Related]
16. Renin-angiotensin system in normotensive and hypertensive patients with progressive systemic sclerosis: hyporesponsiveness of renin during captopril test.
Guillevin L; Leenhardt A; Godeau P
Postgrad Med J; 1983; 59 Suppl 3():171-2. PubMed ID: 6359107
[No Abstract] [Full Text] [Related]
17. Mucin deposits in morphea and systemic scleroderma.
Rongioletti F; Gambini C; Micalizzi C; Pastorino A; Rebora A
Dermatology; 1994; 189(2):157-8. PubMed ID: 8075444
[TBL] [Abstract][Full Text] [Related]
18. Serum levels of soluble interleukin-2 receptor in systemic and circumscribed scleroderma.
Zillikens D; Blum C; Dummer R; Hartmann AA; Burg G
Dermatology; 1992; 184(3):233-4. PubMed ID: 1392125
[No Abstract] [Full Text] [Related]
19. Significance of pentraxin-3 in patients with juvenile scleroderma.
Adrovic A; Sahin S; Barut K; Durmus S; Uzun H; Kasapcopur O
Clin Exp Rheumatol; 2017; 35 Suppl 106(4):221-222. PubMed ID: 28664833
[No Abstract] [Full Text] [Related]
20. Von Willebrand factor propeptide as a marker of disease activity in systemic sclerosis (scleroderma).
Scheja A; Akesson A; Geborek P; Wildt M; Wollheim CB; Wollheim FA; Vischer UM
Arthritis Res; 2001; 3(3):178-82. PubMed ID: 11299058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
